难治性B细胞淋巴瘤CAR-T治疗缓解相关的不同细胞动力学
研究对32例接受axi-cel或tisa-cel治疗的大B细胞淋巴瘤患者的外周血单核细胞和输注产品进行单细胞转录组测序。tisa-cel缓解以增殖性记忆样CD8克隆扩增为特征,axi-cel缓解者细胞群更具异质性;axi-cel无缓解者中CAR-T调节性细胞升高,可在体内模型中抑制常规CAR-T扩增并驱动晚期复发。
要点
- tisa-cel缓解以增殖性记忆样CD8克隆扩增为特征
- axi-cel缓解者细胞群更具异质性
- axi-cel无缓解者CAR-T调节性细胞升高,可驱动晚期复发
核心结论
- 研究揭示CAR-T治疗有效缓解的时间动态、不同设计CAR-T细胞的分子表型差异,以及CAR-T调节性细胞少量增加即可驱动复发。
研究设计与样本
- 对32例接受axi-cel或tisa-cel治疗的大B细胞淋巴瘤患者,采集105份治疗前和治疗后外周血单核细胞样本及输注产品进行单细胞转录组测序。
主要发现
- tisa-cel缓解以增殖性记忆样CD8克隆扩增为特征,而axi-cel缓解者显示更异质性的细胞群。
- 在axi-cel无缓解者中检测到CAR-T调节性细胞升高,这些细胞群在体内模型中能抑制常规CAR-T细胞扩增并驱动晚期复发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. Approximately half of patients with refractory large B cell lymphomas achieve durable responses from CD19-targeting CAR-T treatment; however, failure mechanisms are identified in only a fraction of cases. To gain new insights into the basis of clinical response, we performed single-cell transcriptome sequencing of 105 pretreatment and post-treatment peripheral blood mononuclear cell samples, and infusion products collected from 32 individuals with large B cell lymphoma treated with either of two CD19 CAR-T products: axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel). Expansion of proliferative memory-like CD8 clones was a hallmark of tisa-cel response, whereas axi-cel responders displayed more heterogeneous populations. Elevations in CAR-T regulatory cells among nonresponders to axi-cel were detected, and these populations were capable of suppressing conventional CAR-T cell expansion and driving late relapses in an in vivo model. Our analyses reveal the temporal dynamics of effective responses to CAR-T therapy, the distinct molecular phenotypes of CAR-T cells with differing designs, and the capacity for even small increases in CAR-T regulatory cells to drive relapse.
引用
- Haradhvala NJ, Leick MB, Maurer K, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022. PMID: 36097221. doi:10.1038/s41591-022-01959-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。